Serum Immunoglobulin Levels and Risk of Serious Infections in the Pivotal Phase III Trials of ▼Ocrelizumab in Multiple Sclerosis and Their Open-Label Extensions

Sep 10, 2019 by [Derfuss T, Weber M, Hughes R, Wang Q, Sauter A, Koendgen A, Hauser SL, Bar-Or A, Hartung H-P]

Over 6 years of ▼ocrelizumab treatment, an increasing reduction in serum Ig levels is observed, with an apparent association with increased rates of SIs; The association is strongest for IgG and less so for IgM or IgA. All SIs resolved with standard care, whilst patients continued OCR therapy.

Current View

Receive this presentation and more content via email